Delivering a Diversified Long-term Revenue Stream

Fortress Biotech, Inc. is an innovative biopharmaceutical company focused on delivering a diversified, long-term revenue stream to our shareholders through the creation of a diverse portfolio of marketed products, as well as in-licensing opportunities and through the development of high-potential preclinical and clinical-stage product candidates. Fortress currently has five marketed products and over 25 programs in development.

Recent Event

12th Annual LD Micro Main Event Investor Conference

Latest Financial Results

$9.8M

Fortress’ net revenue totaled $9.8 million for the third quarter of 2019

$9.5M

In the third quarter of 2019, our marketed products generated net revenue of $9.5 million

$156.0M

Fortress’ consolidated cash, cash equivalents, short-term investments (certificates of deposit), and restricted cash totaled $156.0 million

For complete information regarding our financials, see our periodic filings

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2018

mail icon

Sign Up for Email Alerts

Receive updates straight into your inbox

Sign up today

About Fortress Biotech

Fortress Biotech, Inc. (Fortress) is an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potential marketed and development-stage drugs and drug candidates. The company has five marketed products and over 25 programs in development at Fortress, its majority-owned and majority-controlled partners and partners it founded and in which it holds significant minority ownership positions. Such product candidates span large-market therapeutic areas, including oncology, rare diseases and gene therapy, which allow it to create value while mitigating risk for shareholders. Fortress advances its diversified pipeline through a streamlined operating structure that fosters efficient drug development. The Fortress model is driven by a world-class business development team that is focused on leveraging its significant biopharmaceutical industry expertise to further expand the company’s portfolio of product opportunities. Fortress and its partner companies have established partnerships and licensing relationships with some of the world’s leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including Alexion Pharmaceuticals, Inc., City of Hope, Fred Hutchinson Cancer Research Center, InvaGen Pharmaceuticals Inc. (a subsidiary of Cipla Limited) and St. Jude Children’s Research Hospital.

Fortress Biotech at a Glance

25+

Programs in Development

5

Marketed Products

Source

As of Dec. 31, 2018 • 10-K 2018

Fortress Biotech Performance

Year over year company performance

As of Dec. 31, 2018 • 10-K 2018

Our Revenue-Generating Marketed Products

Investor Relations Contacts

Company

Fortress Biotech, Inc.
2 Gansevoort Street
9th Floor
New York, NY 10014
info@fortressbiotech.com

Investor Relations

Jaclyn Jaffe
T: 781-652-4500
ir@fortressbiotech.com

Bill Begien
T: 617-842-2222
bbegien@fortressbiotech.com

Transfer Agent

VStock Transfer, LLC
18 Lafayette Place
Woodmere, NY 11598
T: 212-828-8436
info@vstocktransfer.com
www.vstocktransfer.com